5:36 PM
 | 
Nov 06, 2013
 |  BC Extra  |  Clinical News

NovaBay falls on impetigo miss

NovaBay Pharmaceuticals Inc. (NYSE-M:NBY) said a topical gel formulation of the company's auriclosene ( NVC-422) missed the primary endpoint in a Phase IIb trial to...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >